Sex: F
Vaccine: COVID19
Symptoms: Blood iron, Blood iron decreased, Platelet count, Thrombocytopenia
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of THROMBOCYTOPENIA (blood platelets were low (under 150,000)) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Jul-2021, the patient experienced THROMBOCYTOPENIA (blood platelets were low (under 150,000)) (seriousness criterion medically significant) and BLOOD IRON DECREASED (iron low). The patient was treated with IRON (oral) for Iron low, at an unspecified dose and frequency. At the time of the report, THROMBOCYTOPENIA (blood platelets were low (under 150,000)) and BLOOD IRON DECREASED (iron low) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Jul-2021, Blood iron: low (Low) low. On 01-Jul-2021, Platelet count: under 150,000 (Low) under 150,000.         Concomitant medication of the patient was not reported.  Treatment information for the event platelet count low was not reported by the reporter.  The consumer reported that she had the Moderna COVID-19 vaccine 1st dose on 03-Feb-2021 and 2nd dose on 03-Mar-2021. On 01-Jul-2021, she had her annual physical examination and her doctor noticed that her blood platelets were low (under 150,000). She was given iron tablet [sic] to take because her iron was also found to be low. She will have a repeat blood test on 03-Nov-2021.  This case concerns a female patient, of unknown age, with no relevant medical history, who experienced the unexpected, non-serious AESI of thrombocytopenia with an associated unexpected, non-serious event. The events occurred approximately 3 months after administration of the second dose of the Moderna COVID-19 Vaccine. The rechallenge was not applicable as no additional dosing will be given. The benefit-risk relationship of the Moderna COVID-19 Vaccine is not affected by this report. The event thrombocytopenia was automatically upgraded as serious as per IME list. However, based on the information available and as per medical judgement, the event was assessed as non-serious.; Sender's Comments: This case concerns a female patient, of unknown age, with no relevant medical history, who experienced the unexpected, non-serious AESI of thrombocytopenia with an associated unexpected, non-serious event. The events occurred approximately 3 months after administration of the second dose of the Moderna COVID-19 Vaccine. The rechallenge was not applicable as no additional dosing will be given. The benefit-risk relationship of the Moderna COVID-19 Vaccine is not affected by this report. The event thrombocytopenia was automatically upgraded as serious as per IME list. However, based on the information available and as per medical judgement, the event was assessed as non-serious.